SGLT2 Inhibitors (eg, Empagliflozin) for Diabetes: Pharmacology Review

SGLT2 inhibitors (bexagliflozin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) don’t just lower glucose and A1C, but these meds have become relevant in cardiovascular disease and chronic kidney disease in the right patients also with type 2 diabetes (T2DM). In this lecture from This is Why, Dr. Busti will make the SGLT2 inhibitors make sense as they provide cardiorenal protection above their improvements in A1C.You’ll learn how to:- Mechanism of action (MOA): how SGLT2 blockade drives glucosuria, modest A1c reduction, weight loss, and BP lowering- Clinical use: where SGLT2 inhibitors fit for type 2 diabetes, plus major outcomes in heart failure and chronic kidney disease (CKD) (cardiorenal protection is a key reason they’re prioritized in modern guidelines)- Key drugs (for exams + real-world practice): Empagliflozin (Jardiance), Dapagliflozin (Farxiga), Canagliflozin (Invokana), Ertugliflozin (Steglatro), and Bexagliflozin (Brenzavvy)- Adverse effects & safety pearls: genital mycotic infections, volume depletion/hypotension, AKI considerations, and the “don’t-miss” rare events like euglycemic DKA (plus how to recognize it)The goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/sglt2-inhibitors-canagliflozin-dapagliflozin-empagliflozin-diabetes-pharmacology-reviewGet more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#sglt2inhibitors #empagliflozin #type2diabetes #diabetespharmacology #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.